Results 141 to 150 of about 756,852 (217)

Generalized Myasthenia Gravis with Spasmodic Dysphonia

Journal of the Korean Neurological Association, 2016
Woo-Chan Choi, Sung Jae Heo, Jin-Sung Park   +2 more
openaire   +1 more source

Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study. [PDF]

Adv Ther
Gwathmey KG, Jing P, Laorr S, Koo J, Rakhade S, Sartor EA, Tibung JT, Murray J, Laskar C.   +8 more
europepmc   +1 more source

Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal. [PDF]

Eur J Neurol
Meisel A, Uzawa A, Qi CZ, Nowacek D, Guptill J, Howard JF.   +5 more
europepmc   +1 more source

Complement C5 inhibition in generalized myasthenia gravis is associated with improved survival and increased cardiovascular risk. [PDF]

Front Immunol
Vahldieck C, Fels B.
europepmc   +1 more source

Very Late-Onset Generalized Myasthenia Gravis Presenting With Worsening Frailty. [PDF]

Cureus
Saxena P, Bhutani P, Sachidanand S, Choudhary N, Dhar M.   +4 more
europepmc   +1 more source

Assessing Efgartigimod (VYVGART™) Social Media Posts in Generalized Myasthenia Gravis to Understand Patient, Caregiver, and Health Care Professional Sentiments. [PDF]

Neurol Ther
Hughes T, Whangbo A, Shukla S, Batra A, Bhattacharya K, Sharma A, Jarmale S.   +6 more
europepmc   +1 more source

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis. [PDF]

Adv Ther
Jacob S, Hashim M, Hutton B, Gandhi K, Van Sanden S, Slowik R, Drudge C, Khoury ACE, Keng MJ, Singh S, Ramchandren S, Gilhus NE.   +11 more
europepmc   +1 more source

Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Yasuda M, Uzawa A, Handa H, Ogaya E, Kurumada K, Takasaka K, Mori M, Kuwabara S.   +7 more
europepmc   +1 more source

Steroid-Sparing Effect of Efgartigimod in Generalized Myasthenia Gravis: Study Protocol for a Single-Arm, Open-Label Clinical Trial. [PDF]

Neurol Ther
Suzuki T, Fujimaki M, Ohuchi S, Hosaka T, Shioya A, Saiki S.   +5 more
europepmc   +1 more source

Characterizing and quantifying disease impacts of generalized myasthenia gravis (gMG) in the United States: insights from patient and caregiver interviews and surveys. [PDF]

J Patient Rep Outcomes
Narayanaswami P, Sullivan J, Thiele C, Ramirez C, dosReis S, Foss A, Yee KS, Rebeira M, Wahid N, Garduno AC, Crevier E, Rowe C, Gwathmey KG.   +12 more
europepmc   +1 more source